Key Highlights
- Shares of PBM climbed as high as 203.8% on April 16, 2026, following reports that the White House plans to issue an executive order supporting ibogaine research initiatives.
- Psyence Biomedical announced the expansion of its Australian clinical trial infrastructure from three to five locations for its NPX-5 Phase IIb psilocybin program.
- The company postponed its previously scheduled 1-for-6.25 reverse stock split, maintaining current trading conditions.
- Market observers attribute the rally to speculative momentum and limited float rather than fundamental business developments.
- With a market capitalization of only $11.63 million and a GF Score of 20/100, PBM remains highly speculative with a profitability score of 1/10.
Shares of Psyence Biomedical (PBM) experienced extraordinary volatility on April 16, 2026. The micro-cap biotech company saw its stock price triple after reports emerged that the White House intends to issue an executive order promoting research into ibogaine, a psychedelic substance being explored for PTSD and various mental health disorders.
According to Quiver PriceTracker data, PBM finished trading up roughly 203.8% for the day. GuruFocus tracking showed intraday gains reaching approximately 105.96% at certain points during the session.
The anticipated White House action represents a notable policy evolution in federal attitudes toward psychedelic medicine. Ibogaine has attracted attention from researchers investigating treatments for substance addiction and psychological trauma, and the executive order would facilitate expanded clinical investigation.
While Psyence Biomedical’s primary research focus centers on natural psilocybin rather than ibogaine, the company benefited substantially from the positive sentiment sweeping across the psychedelic therapeutics sector.
Trial Network Growth Contributes to Momentum
Beyond the favorable regulatory environment, PBM released company-specific developments that added to investor enthusiasm. The firm disclosed an expansion of its Australian clinical trial infrastructure, increasing from three to five operational sites. This enhancement supports the ongoing Phase IIb clinical work for NPX-5, its naturally-derived psilocybin candidate designed to address Adjustment Disorder in cancer patients undergoing palliative treatment.
The expanded site network aims to accelerate patient enrollment and sustain dosing activities throughout the study. These details were formally disclosed through an SEC Form 6-K filing in April 2026.
Notably, no fresh clinical efficacy or safety results were published on April 16. Market analysts emphasize that the price movement reflected speculative trading dynamics, with limited liquidity magnifying price volatility.
Additionally, the company verified that it has delayed its planned 1-for-6.25 reverse stock split. The stock continues to trade without adjustment pending announcement of a revised implementation date. This decision preserved the existing share structure and may have intensified the short-squeeze-style price action.
Financial Profile and Metrics
Psyence Biomedical operates as a micro-cap entity with a current market valuation of approximately $11.63 million. Prior to the rally, shares were changing hands near $5.08 — significantly below the 52-week peak of $74.94.
The company’s GF Score registers at 20 out of 100. While financial strength achieves an 8/10 rating, profitability scores merely 1/10. No price-to-earnings ratio exists due to negative earnings performance.
Institutional ownership remains minimal. During Q4 2025, five institutional holders reduced or eliminated their positions entirely. Parallel Advisors liquidated its complete stake of 151,250 shares. UBS Group represented the sole new institutional buyer, acquiring 1,007 shares.
No insider transactions—either purchases or sales—have been documented over the trailing twelve months.
The company maintains a federally licensed psilocybin cultivation operation in Southern Africa and distributes products to international research partners.
As of April 16, 2026, Psyence Biomedical has not generated revenue and remains unprofitable, with its clinical pipeline still progressing through mid-stage development phases.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
